Since the Food and Drug Administration (FDA) approval of anti-CTLA-4 antibody ipilimumab in 2011, several antibodies targeting PD-1/programmed death-ligand 1 (PD-L1) immune checkpoint pathway have been approved for cancer therapy in various indications with many more in the pipeline (2). Here, PDCD1 is linked to cancer.